PLAIO

Sidekick is a patient-centric digital care platform that is scalable across a wide range of chronic illnesses. It delivers industry-leading retention and clinical impact on health outcomes including cardiovascular fitness, weight, blood glucose, quality of life, fatigue, and medication adherence. The Sidekick platform combines an evidence-based clinical approach with behavioral economics and gamification. It helps global customers like Pfizer and Bayer expand therapy reach and impact across multiple therapeutic areas and diseases, operating in multiple countries. The platform is a CE-marked, Class I Medical Device.

Kerecis creates licensed fish-skin items to mend the human body. Since no sickness move risk exists between chilly water fish and people, the Kerecis fish skin is just delicately handled and holds its closeness to human skin, making it an optimal substitute for human skin. In excess of 50 examinations have been finished on Kerecis innovation. Those reviews incorporate two twofold visually impaired, near, randomized control preliminaries, where fish skin treatment was more solid than mammalian-based medicines. Kerecis is likewise creating items for regions like oral medical procedure, plastic medical procedure, and neurological applications. The organization's items use various licensed unsaturated fat advancements to secure and recover tissue across two center innovations like Kerecis Omega3 Fish Skin and Kerecis Omega3 Viruxide.

PLAIO is a web-based SaaS platform intended to help generic pharmaceutical companies to digitize their demand, manufacturing, and purchase planning.PLAIO offers features like visual and capacity planning, advanced constraint/overhead calculations.

EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the enhancement of epithelial barrier integrity as a causal pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human skin and lung tissue, as well as the intestinal tract and genitalia. Compromised integrity of this barrier is implicated in the progression and non-resolution of inflammation. EpiEndo is developing a proprietary portfolio of orally available macrolide drug candidates with promise as first-in-class disease-modifying therapeutics, to address the huge global burden of chronic respiratory diseases and other significant unmet medical needs. EpiEndo’s lead drug candidate, EP395, aims to be the first on-market oral, disease modifying, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for COPD and other inflammatory airway diseases.

Neko Health, a health-tech company from Sweden, aims to develop a healthcare system that promotes the maintenance of good health through preventive measures and early detection. Their innovative medical scanning technology concept enables the convenient and cost-effective collection of comprehensive health data, without the need for invasive procedures, making it accessible to the general public.

A medical device firm called 410 Medical is committed to creating cutting-edge technologies that help doctors provide better treatment for seriously ill patients. The recently approved LifeFlow® PLUS device from 410 is intended to increase the speed and effectiveness of volume resuscitation, enhancing the treatment of patients with life-threatening illnesses such sepsis, bleeding, and cardiac arrest.

Fibroheal Woundcare Pvt Ltd focuses on leveraging silk proteins to create biomedical applications for effective wound care. The company develops advanced medical devices aimed at addressing various types of wounds, including acute and chronic cases.

Leo Cancer Care provides a streamlined and effective treatment method that empowers patients and instills hope. Founded in Australia, Leo Cancer Care is grounded in international research on the advantages of upright patient positioning. Through a shift from machine rotation to patient rotation, Leo Cancer Care is positioned to revolutionize radiation therapy.

Handspring is redesigning the family mental healthcare experience from the ground up. Our omnichannel care delivery model tightly integrates different modalities of care, including in-person, digital and devices. Through the use of technology, health plan partnerships, and highly trained clinicians. Handspring Health aims to make quality mental healthcare more accessible to all families.

Ognomy is transforming the $10B+ sleep health market by delivering fast, convenient, insured virtual care for obstructive sleep apnea (OSA). With a 50-state sleep medicine clinician network and in-network coverage for 200M+ lives, Ognomy makes high-quality sleep apnea care accessible at national scale. Our proprietary cloud platform, enhanced by AI-driven workflow tools, streamlines operations and empowers clinicians — enabling faster diagnosis and better patient outcomes while maintaining a patient-first approach. With 25,000+ patients cared for and an 81 NPS, our results speak for themselves.

LTC Properties, Inc. is a self-administered real estate investment trust that invests primarily in the long-term care sector of the health care industry through the origination of first mortgage loans and acquisition of properties that are leased to numerous long-term care providers. LTC Properties operates in accordance with federal tax laws and regulation governing real estate investment trusts, which enables the Company's income to be distributed to its stockholders without federal tax liability to the Company.

CraniUS is a manufacturer of medical equipment.